BIOCRYST PHARMACEUTICALS INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Biocryst Pharmaceuticals Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Biocryst Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$14M, a 61.2% increase year-over-year.
  • Biocryst Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$124M, a 47.6% increase year-over-year.
  • Biocryst Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$227M, a 8.33% increase from 2022.
  • Biocryst Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$247M, a 34.3% decline from 2021.
  • Biocryst Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$184M, a 0.68% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$124M -$14M +$22.1M +61.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$146M -$12.7M +$62.7M +83.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-05
Q1 2024 -$209M -$35.4M +$18M +33.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-05
Q4 2023 -$227M -$61.7M +$9.81M +13.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$236M -$36.1M +$6.37M +15% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$243M -$75.3M -$16.5M -28% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-05
Q1 2023 -$226M -$53.3M +$20.9M +28.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-05
Q4 2022 -$247M -$71.5M -$53.8M -302% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 -$193M -$42.5M +$16.3M +27.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$210M -$58.9M -$15.7M -36.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$194M -$74.2M -$9.91M -15.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$184M -$17.8M +$42.7M +70.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$227M -$58.8M -$12.7M -27.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 -$214M -$43.2M -$4.59M -11.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-04
Q1 2021 -$209M -$64.3M -$26.7M -71% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-04
Q4 2020 -$183M -$60.5M -$57.9M -2207% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$125M -$46.1M -$8.52M -22.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$116M -$38.6M -$978K -2.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$115M -$37.6M -$6.55M -21.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$109M -$2.62M +$24.8M +90.4% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$134M -$37.6M -$8M -27% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$126M -$37.6M -$19.2M -104% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$107M -$31.1M -$5.28M -20.5% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$101M -$27.4M -$7.89M -40.4% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-13
Q3 2018 -$93.4M -$29.6M -$14.5M -95.6% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-13
Q2 2018 -$78.9M -$18.4M -$1.56M -9.24% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-13
Q1 2018 -$77.3M -$25.8M -$11.6M -81.3% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-13
Q4 2017 -$65.8M -$19.5M -$15M -334% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$50.7M -$15.1M -$3.61M -31.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-14
Q2 2017 -$47.1M -$16.9M -$605K -3.72% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-14
Q1 2017 -$46.5M -$14.2M +$8.61M +37.7% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-14
Q4 2016 -$55.1M -$4.5M +$13.6M +75.2% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-12
Q3 2016 -$68.8M -$11.5M +$3.09M +21.2% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-12
Q2 2016 -$71.9M -$16.3M -$21.2M -432% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-12
Q1 2016 -$50.7M -$22.8M -$7.67M -50.6% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-12
Q4 2015 -$43M -$18.1M -$6.46M -55.4% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-27
Q3 2015 -$36.6M -$14.6M -$5.89M -67.5% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-27
Q2 2015 -$30.7M $4.9M +$19.6M Apr 1, 2015 Jun 30, 2015 10-K 2017-02-27
Q1 2015 -$50.2M -$15.2M -$5.03M -49.6% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-27
Q4 2014 -$45.2M -$11.7M -$6.24M -115% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-26
Q3 2014 -$38.9M -$8.73M -$730K -9.12% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-26
Q2 2014 -$38.2M -$14.6M -$2.48M -20.4% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-26
Q1 2014 -$35.7M -$10.1M -$5.63M -125% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-26
Q4 2013 -$30.1M -$5.43M +$5.62M +50.9% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-02
Q3 2013 -$35.7M -$8M +$1.7M +17.5% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-02
Q2 2013 -$37.4M -$12.2M +$104K +0.85% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-02
Q1 2013 -$37.5M -$4.51M +$1.55M +25.5% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-02
Q4 2012 -$39.1M -$11.1M +$2.14M +16.2% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-10
Q3 2012 -$41.2M -$9.7M +$4.76M +32.9% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-10
Q2 2012 -$46M -$12.3M +$4M +24.6% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-10
Q1 2012 -$50M -$6.05M +$6.98M +53.5% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-10
Q4 2011 -$56.9M -$13.2M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-11
Q3 2011 -$14.5M -$3.6M -33.1% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-11
Q2 2011 -$16.3M -$6.08M -59.6% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-11
Q1 2011 -$13M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-11
Q3 2010 -$10.9M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-03
Q2 2010 -$10.2M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.